Sol-Gel Secures Patent Extension for Patidegib Until 2044, Raises $33.1M to Advance Gorlin Syndrome Trial
核心洞察
Sol-Gel Technologies received a Notice of Allowance for a method-of-use patent extending intellectual property protection for topical patidegib (SGT-610) until 2044, significantly strengthening the commercial potential of their lead candidate.
The company completed an oversubscribed underwritten offering raising gross proceeds of approximately $33.1 million from leading healthcare specialist investors to fund continued development of SGT-610.
The pivotal Phase 3 clinical trial of SGT-610 for Gorlin syndrome (搜索) remains on track with top-line results anticipated in the fourth quarter of 2026.
Sol-Gel Technologies achieved two major corporate milestones in the first quarter of 2026, securing extended patent protection for its lead investigational therapy and raising significant capital to advance its pivotal clinical program. The dermatology company received a Notice of Allowance from the U.S. Patent and Trademark Office for a method-of-use patent covering topical patidegib (SGT-610) that extends intellectual property protection until 2044, while simultaneously completing an oversubscribed $33.1 million financing round.
Patent Protection Strengthens Commercial Position
The Notice of Allowance for U.S. Patent Application No. 19/266,342 covers a method-of-use that Sol-Gel describes as "critical to successful topical patidegib therapy." This patent extension until 2044 represents a significant milestone for SGT-610, the company's Phase 3, orphan- and breakthrough-designated topical hedgehog (搜索) inhibitor being developed for preventing new basal cell carcinoma (搜索) (BCC) lesions in patients with Gorlin syndrome (搜索).
"The Notice of Allowance extending the exclusivity of patidegib until 2044 marks a major milestone in the value creation of SGT-610 and Sol-Gel as a company," stated Mori Arkin, Executive Chairman of Sol-Gel. "We believe that the combination of our March 2026 financing and the Notice of Allowance for a method-of-use patent protecting topical patidegib until 2044 fundamentally reshapes the long-term opportunity for SGT-610."
Oversubscribed Financing Supports Clinical Development
The company's March 2026 underwritten offering of 459,112 ordinary shares at $72.00 per share generated gross proceeds of approximately $33.1 million before underwriting discounts and expenses. The offering attracted participation from new and existing investors, including Great Point Partners, LLC, Trails Edge Capital Partners, Surveyor Capital (a Citadel company), Affinity Asset Advisors, Squadron Capital Management, Stonepine Capital Management and AuGC BioFund.
Sol-Gel intends to use the net proceeds to fund continued development of SGT-610, including pre-commercialization activities and research and development, with the remainder allocated to working capital and general corporate purposes. The company expects its cash resources to fund operations into the first quarter of 2028.
Phase 3 Trial Progresses Toward Key Readout
Sol-Gel's pivotal Phase 3 clinical trial of SGT-610 for Gorlin syndrome (搜索) continues to advance, with the company maintaining its timeline for top-line results in the fourth quarter of 2026. Additionally, preparations are ongoing for a proof-of-concept study of SGT-610 in high-frequency BCC, which Arkin noted "could double the commercial potential of patidegib."
SGT-610 is designed to offer an improved safety profile relative to oral hedgehog (搜索) inhibitors currently used to treat patients with Gorlin syndrome (搜索), a rare genetic condition that predisposes individuals to developing multiple BCCs throughout their lifetime.
Global Commercialization Strategy Expands
In April 2026, Sol-Gel entered into an exclusive license agreement with Sun Pharmaceutical Industries Ltd. for the commercialization of TWYNEO® in India. This agreement adds to eight previous agreements signed during 2024 and 2025 for the commercialization of TWYNEO® and EPSOLAY in various territories covering most European countries, South Africa, South Korea, Australia and New Zealand.
Based on forecasts from current and potential partners, Sol-Gel expects TWYNEO and EPSOLAY to launch in the majority of these new territories during 2028 and 2027 respectively. The company anticipates these transactions will provide an annual royalty revenue stream with the potential to reach approximately $10 million by 2031.
Financial Performance and Outlook
For the first quarter of 2026, Sol-Gel reported revenue of $0.1 million compared to $1.0 million in the same period of 2025, primarily due to a milestone payment from Searchlight in the prior year quarter. Research and development expenses decreased significantly to $2.8 million from $8.8 million in the first quarter of 2025, largely attributed to reduced expenses associated with supplier-led manufacturing development and clinical trial activities.
The company reported a net loss of $3.7 million for the first quarter of 2026, or $1.31 per basic and diluted share, compared to a net loss of $8.8 million, or $3.20 per share, for the same period in 2025. As of March 31, 2026, Sol-Gel maintained $52.8 million in total cash, cash equivalents, deposits and marketable securities.